BDO Wealth Advisors’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
Sell
-130
Closed -$3K 624
2019
Q2
$3K Sell
130
-3,283
-96% -$67.6K ﹤0.01% 557
2019
Q1
$72K Buy
+3,413
New +$71.6K 0.02% 248

Other funds holding CNCR

BDO Wealth Advisors's CNCR Position: Q3 2019 in Review

BDO Wealth Advisors sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q3 2019, closing a stake of 130 shares — an estimated $3K sold.

BDO Wealth Advisors first reported a position in CNCR in Q1 2019 and held it in 2 quarters. The position peaked at $72K in Q1 2019. 22 funds tracked by Wall St. Rank hold CNCR as of Q3 2019.

  • BDO Wealth Advisors reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q3 2019 after selling out during the quarter.
  • BDO Wealth Advisors sold 130 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q3 2019, an estimated $3K.
  • BDO Wealth Advisors first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q1 2019 and held it in 2 quarters.
  • BDO Wealth Advisors's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $72K in Q1 2019.
  • 22 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q3 2019.

Based on BDO Wealth Advisors's 13F filing for Q3 2019, filed 12 Nov 2019.